For other immune checkpoint proteins, such as CTLA-4, TIGIT, TIM-3, and LAG-3, their evaluation in PTCL is still at the preclinical stage and needs to be validated via relevant clinical trials. Here, LAG3 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.